Avalo Therapeutics, Inc. Common Stock
Symbol: AVTX (NASDAQ)
4.43
▼ (-4.01%) -0.185
Company Description:
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).
Key Stats
- Today's Open: $4.6
- Today's High: $4.685
- Today's Low: $4.336
- Today's Volume: 66.74K
- Yesterday Close: $4.61
- Yesterday High: $4.9
- Yesterday Low: $4.6
- Yesterday Volume: 28.73K
- Last Min Volume: 250
- Last Min High: $4.425
- Last Min Low: $4.425
- Last Min VWAP: $4.425
Company Profile
- Name: Avalo Therapeutics, Inc. Common Stock
- Website: https://www.avalotx.com
- Listed Date: 2015-11-13
- Location: WAYNE, PA
- Market Status: Active
- CIK Number: 0001534120
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $52.19M
- Round Lot: 100
- Outstanding Shares: 10.83M
- Asset Type: CS
RECENT FILINGS FOR AVTX
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-06-17 | 8-K | View |
| 2025-06-05 | 8-K | View |
| 2025-06-05 | 424B5 | View |
| 2025-06-04 | 8-K | View |
| 2025-05-15 | SCHEDULE 13G/A | View |
| 2025-05-15 | SCHEDULE 13G/A | View |
| 2025-05-15 | SCHEDULE 13G | View |
| 2025-05-12 | S-8 | View |
| 2025-05-12 | S-8 | View |
| 2025-05-12 | 10-Q | View |
| 2025-05-12 | 8-K | View |
| 2025-05-08 | 8-K | View |
| 2025-05-01 | ARS | View |
| 2025-05-01 | DEFA14A | View |
| 2025-05-01 | DEF 14A | View |
| 2025-04-01 | 4 | View |
| 2025-04-01 | 4 | View |
| 2025-04-01 | 4 | View |
| 2025-04-01 | 4 | View |
| 2025-04-01 | 4 | View |
Latest News on AVTX